FDA Finalizes Guidance on CMC Submissions for Gene Therapies

A A
The FDA is detailing its expectations for chemistry, manufacturing and control information that is included in INDs for gene therapies.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $10.00